CoChat

Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment

Open access
Kenny, Aidan, McArdle, Hazel, Calero, Miguel, Rabano, Alberto, Madden, Stephen F., Adamson, Kellie, Forster, Robert, Spain, Elaine, Prehn, Jochen H.M., Henshall, David C., Medina, Miguel, Jimenez-Mateos, Eva M., Engel, Tobias · 2019 · SSRN Electronic Journal
Cited by 71

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: With pre-symptomatic stages of Alzheimer's disease (AD) becoming the primary target for therapeutic intervention, there is an unmet need for practical biomarkers to facilitate the diagnosis of these early disease stages. MicroRNAs, small non-coding RNAs with a high stability in extracellular environments, are a promising source of accessible biomarkers. In this study we investigated the use of blood-based microRNAs as prognostic biomarkers for the development of dementia and diagnosis of AD.Methods: MicroRNAs were profiled via a genome-wide high-throughput platform in plasma from patients with mild cognitive impairment (MCI) and clinical AD. Identified candidate microRNAs were verified by individual RT-qPCR and a novel electrochemical detection system. Subjects were recruited as part of a longitudinal aging study and underwent annual clinical assessments and blood sampling.Findings: Let-7b and microRNA-206 were identified at elevated levels in MCI and dementia and AD, respectively. MicroRNA-206 displayed a strong correlation with cognitive decline and memory deficits. Longitudinal follow up over 5 years identified microRNA-206 increases preceding the onset of dementia. MiR-206 was also detected at increased concentrations in unprocessed plasma of AD and MCI subjects using a microfluidic device.Interpretation: While increased Let-7b levels in plasma may be used to identify patients with MCI, changes in plasma levels of microRNA-206 may be used to predict cognitive decline and progression towards dementia at an MCI stage. MicroRNA quantification via a microfluidic device could provide a practical cost-effective tool for stratification of patients with MCI according to risk of developing AD.Funding Statement: This work was supported by funding from the Health Research Board HRA-POR-2015-1243 to TE; Science Foundation Ireland (17/CDA/4708 to T.E, 18/FIP/3552 to ES and KA, and co-funded under the European Regional Development Fund and by FutureNeuro industry partners 16/RC/3948 to DCH) and funding from CIBERNED and the Spanish Ministry of Science (SAF2016-78603-R) to MM and MC. The Vallecas Project is supported by institutional grants from the Queen Sofia Foundation, CIEN Foundation and the Carlos III Institute of Health. Declaration of Interests: This work was supported by funding from the Health Research Board HRA-POR-2015-1243 to TE; Science Foundation Ireland (17/CDA/4708 to T.E, 18/FIP/3552 to ES and KA, and co395 funded under the European Regional Development Fund and by FutureNeuro industry partners 16/RC/3948 to DCH) and funding from CIBERNED and the Spanish Ministry of Science (SAF2016-78603-R) to MM and MC. The Vallecas Project is supported by institutional grants from the Queen Sofia Foundation, CIEN Foundation and the Carlos III Institute of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors have declared no conflict of interest.Ethics Approval Statement: The project was approved by the Ethics Committee of the Carlos III Institute of Health. All participants provided written informed consent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2139/ssrn.3429882

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 71

Metadata

Authors
Kenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., Medina, M., Jimenez-Mateos, E. M., & Engel, T.
Venue
SSRN Electronic Journal
Publisher
Elsevier BV
Published
2019
Volume
9
Issue
11
Pages
734-734
ISSN
  • 2218-273X (ISSN-L)
  • 1556-5068
OpenAlex
W2989531900
Cited by
71
References
15
FWCI
7.03
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. https://app.cochat.ai/papers/10.2139/ssrn.3429882
The paper
Kenny, A., McArdle, H., Calero, M., Rabano, A., Madden, S. F., Adamson, K., Forster, R., Spain, E., Prehn, J. H. M., Henshall, D. C., Medina, M., Jimenez-Mateos, E. M., & Engel, T. (2019). Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3429882

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.